Helix Historical Financial Ratios
| HBP Stock | CAD 0.87 0.04 4.82% |
Helix BioPharma is recently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 74.71 or Invested Capital of 0.0 will help investors to properly organize and evaluate Helix BioPharma Corp financial condition quickly.
Helix |
About Helix Financial Ratios Analysis
Helix BioPharma CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Helix BioPharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Helix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Helix BioPharma history.
Helix BioPharma Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Helix BioPharma Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Helix BioPharma sales, a figure that is much harder to manipulate than other Helix BioPharma Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Helix BioPharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Helix BioPharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Helix BioPharma's Days Payables Outstanding is very stable compared to the past year. As of the 30th of November 2024, Income Quality is likely to grow to 0.73, while PTB Ratio is likely to drop (596.85).
| 2023 | 2024 (projected) | Payables Turnover | 0.0164 | 0.0156 | Days Of Inventory On Hand | 4.5K | 4.7K |
Helix BioPharma fundamentals Correlations
Click cells to compare fundamentals
Helix BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Helix Stock
Moving against Helix Stock
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Helix BioPharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Helix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Helix BioPharma history.